| 1 | two | 128,466 |
| 2 | odd-numbered | 15 |
| 3 | tow | 11 |
| 4 | eplerenone-treated | 9 |
| 5 | non-chemotherapy | 8 |
| 6 | tc-dcr | 6 |
| 7 | jinsane-treated | 5 |
| 8 | pemetrexed-containing | 5 |
| 9 | 1.0-gy | 4 |
| 10 | fgf-treated | 4 |
| 11 | lido-lido | 4 |
| 12 | non-pheromonal | 4 |
| 13 | pre-optimised | 4 |
| 14 | 'two | 3 |
| 15 | apigenin-treated | 3 |
| 16 | cf-treated | 3 |
| 17 | ethno-racial | 3 |
| 18 | five-viscera | 3 |
| 19 | high-fluorine | 3 |
| 20 | lovastatin-placebo | 3 |
| 21 | low/low-intermediate | 3 |
| 22 | no-compression | 3 |
| 23 | non-td | 3 |
| 24 | oil-infused | 3 |
| 25 | peg-treated | 3 |
| 26 | 1,000-mg/day | 2 |
| 27 | 2d-3 | 2 |
| 28 | 3,000-mg/day | 2 |
| 29 | 3,178 | 2 |
| 30 | 3,4-dimethyl | 2 |
| 31 | 320-μg | 2 |
| 32 | alpha-blocker-naive | 2 |
| 33 | azl-m/cld | 2 |
| 34 | boc-containing | 2 |
| 35 | bol-treated | 2 |
| 36 | bpa-treated | 2 |
| 37 | ca-fed | 2 |
| 38 | cholecalciferol-supplemented | 2 |
| 39 | da-9601-treated | 2 |
| 40 | dbp-only | 2 |
| 41 | electropolymerizable | 2 |
| 42 | enalapril-hydrochlorothiazide | 2 |
| 43 | f145 | 2 |
| 44 | imrt+3dcrt | 2 |
| 45 | interviews/focus | 2 |
| 46 | m-turp/b-turp | 2 |
| 47 | medium-/low-potency | 2 |
| 48 | metal-exposed | 2 |
| 49 | microcapsule-treated | 2 |
| 50 | nanocapsules-treated | 2 |
| 51 | no-ae | 2 |
| 52 | non-classified | 2 |
| 53 | nzl-treated | 2 |
| 54 | omom | 2 |
| 55 | oswe-treated | 2 |
| 56 | phosphazene | 2 |
| 57 | placebo-prednisolone | 2 |
| 58 | propranolol/hydrochlorothiazide-treated | 2 |
| 59 | right-to-life | 2 |
| 60 | small-n | 2 |
| 61 | tensorial | 2 |
| 62 | us+ns | 2 |
| 63 | 'rolling | 1 |
| 64 | 2',3'-bisphosphorothioate | 1 |
| 65 | 2',3'-o-acyl | 1 |
| 66 | 2',3'-o-silyl | 1 |
| 67 | 2,2'-alkyl | 1 |
| 68 | 2,3-dihydroxyl | 1 |
| 69 | 2,3-hydroxyl | 1 |
| 70 | 2,904 | 1 |
| 71 | 2000-u | 1 |
| 72 | 22,479 | 1 |
| 73 | 27,955 | 1 |
| 74 | 3,5-dihydroxyl | 1 |
| 75 | 4,343 | 1 |
| 76 | 4-eth-oxy-phenyl | 1 |
| 77 | 4-phenoxyaryl | 1 |
| 78 | 40-and-over | 1 |
| 79 | 47/68 | 1 |
| 80 | 4d-transition-metal-doped | 1 |
| 81 | 5,6-epoxide | 1 |
| 82 | 5-htt-linked | 1 |
| 83 | 500-lux | 1 |
| 84 | abciximab/ticlopidin/aspirin-treated | 1 |
| 85 | acrh-treated | 1 |
| 86 | acrydite | 1 |
| 87 | adjustment-disorder | 1 |
| 88 | aerials | 1 |
| 89 | alcohol/chlorhexidine | 1 |
| 90 | alcoholic-septic | 1 |
| 91 | almond-consuming | 1 |
| 92 | amino/amine | 1 |
| 93 | antónio | 1 |
| 94 | ap-exposed | 1 |
| 95 | apigenintreated | 1 |
| 96 | ar-6-treated | 1 |
| 97 | ar/asr | 1 |
| 98 | ara-administrated | 1 |
| 99 | arsonate | 1 |
| 100 | atv-treatment | 1 |
| 101 | authors.two | 1 |
| 102 | borates-bo3 | 1 |
| 103 | butein-treated | 1 |
| 104 | carbometh-oxy | 1 |
| 105 | ccpi-containing | 1 |
| 106 | cediranib-containing | 1 |
| 107 | cgx-treated | 1 |
| 108 | cokriging | 1 |
| 109 | compression-treated | 1 |
| 110 | conivaptan-treated | 1 |
| 111 | consumer-run | 1 |
| 112 | control/auriculotherapy | 1 |
| 113 | control/experimental | 1 |
| 114 | conventional-method | 1 |
| 115 | coumestan-treated | 1 |
| 116 | cr-fed | 1 |
| 117 | cultural/linguistic | 1 |
| 118 | daphnetin-treated | 1 |
| 119 | data.three | 1 |
| 120 | dbaa-treated | 1 |
| 121 | dexamethasone-containing | 1 |
| 122 | dibenzylamido | 1 |
| 123 | dinitroamino | 1 |
| 124 | discovery/validation | 1 |
| 125 | dm/chd | 1 |
| 126 | drug-switching | 1 |
| 127 | effects.clinical | 1 |
| 128 | eifferent | 1 |
| 129 | emg- | 1 |
| 130 | enoximone-treated | 1 |
| 131 | ester-coo | 1 |
| 132 | eth-oxy | 1 |
| 133 | evacetrapib-treated | 1 |
| 134 | evar-related | 1 |
| 135 | evogliptin-treated | 1 |
| 136 | exposure-level | 1 |
| 137 | fbg-treated | 1 |
| 138 | fibrillogenic | 1 |
| 139 | filamenting | 1 |
| 140 | four-doses | 1 |
| 141 | furanodiene-treated | 1 |
| 142 | ground/heat-treated | 1 |
| 143 | ground/non-heat-treated | 1 |
| 144 | guadino | 1 |
| 145 | hcd-alone | 1 |
| 146 | hr-treated | 1 |
| 147 | ht/db | 1 |
| 148 | iacr-iach | 1 |
| 149 | ifx/ssz+hcq | 1 |
| 150 | implants.three | 1 |
| 151 | intervention.one | 1 |
| 152 | intervention/support | 1 |
| 153 | involved.three | 1 |
| 154 | ir+sjhxt | 1 |
| 155 | isopentene | 1 |
| 156 | isspp-treated | 1 |
| 157 | least-researched | 1 |
| 158 | lgi/hgi | 1 |
| 159 | low-fat-fed | 1 |
| 160 | low-solidarity | 1 |
| 161 | low/high-fat | 1 |
| 162 | lp/hp | 1 |
| 163 | metaphosphate | 1 |
| 164 | methoxynaphthalene | 1 |
| 165 | methyl-carboxyl-ate | 1 |
| 166 | militant | 1 |
| 167 | morse-tapered | 1 |
| 168 | msdc-0160-treated | 1 |
| 169 | new-model | 1 |
| 170 | newly-defined | 1 |
| 171 | nfv-treatment | 1 |
| 172 | no-reminder | 1 |
| 173 | non-bns | 1 |
| 174 | non-cephalosporin-based | 1 |
| 175 | non-gcae | 1 |
| 176 | non-impulsive | 1 |
| 177 | non-ohqi | 1 |
| 178 | non-pdt | 1 |
| 179 | non-prototypical | 1 |
| 180 | non-pvd | 1 |
| 181 | nonadjuvanted-vaccine | 1 |
| 182 | nonstigmatized | 1 |
| 183 | oligonucleosome-sized | 1 |
| 184 | olm-treated | 1 |
| 185 | ortho-dihydroxy | 1 |
| 186 | ovx+mlt | 1 |
| 187 | pee-epee | 1 |
| 188 | phthalimido | 1 |
| 189 | phy-sicians/lab | 1 |
| 190 | picky/non-picky | 1 |
| 191 | picolinamide | 1 |
| 192 | picolinyl | 1 |
| 193 | ple-treated | 1 |
| 194 | pnp-treated | 1 |
| 195 | postmicturition-only | 1 |
| 196 | ppci-alone | 1 |
| 197 | precut-cannulation | 1 |
| 198 | reinstitutionalization | 1 |
| 199 | rhfgf-2-treated | 1 |
| 200 | risk/intervention | 1 |
| 201 | s-ketamine-pca | 1 |
| 202 | sea-caged | 1 |
| 203 | seeds/control | 1 |
| 204 | selegiline/rasagiline | 1 |
| 205 | selenium-treatment | 1 |
| 206 | self-vaginal | 1 |
| 207 | single-medication | 1 |
| 208 | so3h | 1 |
| 209 | socs3-based | 1 |
| 210 | sofosbuvir/pegifn/rbv | 1 |
| 211 | spirotetrahydroselenophene | 1 |
| 212 | standard-method | 1 |
| 213 | standard-model | 1 |
| 214 | std-risk | 1 |
| 215 | steroid-administered | 1 |
| 216 | stimulant-containing | 1 |
| 217 | sulfonamide-treated | 1 |
| 218 | superfamilial | 1 |
| 219 | supplement-administration | 1 |
| 220 | tbc-treated | 1 |
| 221 | tcbz-treated | 1 |
| 222 | techniques.three | 1 |
| 223 | thre | 1 |
| 224 | ti-oh | 1 |
| 225 | to-treated | 1 |
| 226 | trans-dehydrocrotonin-treated | 1 |
| 227 | treatment/normative | 1 |
| 228 | treatments.six | 1 |
| 229 | two-drug-combination | 1 |
| 230 | uniform-sized | 1 |
| 231 | unsponsored | 1 |
| 232 | vcd- | 1 |
| 233 | vector+gdcl3 | 1 |
| 234 | vit-c-supplemented | 1 |
| 235 | wheat-cereal | 1 |
| 236 | wire-guided-cannulation | 1 |
| 237 | wlc-only | 1 |
| 238 | wyfc-lnd | 1 |
| 239 | younger/older/elderly | 1 |
| 240 | –nh– | 1 |
| 1 | 'rolling | 1 |
| 2 | 'two | 3 |
| 3 | 1,000-mg/day | 2 |
| 4 | 1.0-gy | 4 |
| 5 | 2',3'-bisphosphorothioate | 1 |
| 6 | 2',3'-o-acyl | 1 |
| 7 | 2',3'-o-silyl | 1 |
| 8 | 2,2'-alkyl | 1 |
| 9 | 2,3-dihydroxyl | 1 |
| 10 | 2,3-hydroxyl | 1 |
| 11 | 2,904 | 1 |
| 12 | 2000-u | 1 |
| 13 | 22,479 | 1 |
| 14 | 27,955 | 1 |
| 15 | 2d-3 | 2 |
| 16 | 3,000-mg/day | 2 |
| 17 | 3,178 | 2 |
| 18 | 3,4-dimethyl | 2 |
| 19 | 3,5-dihydroxyl | 1 |
| 20 | 320-μg | 2 |
| 21 | 4,343 | 1 |
| 22 | 4-eth-oxy-phenyl | 1 |
| 23 | 4-phenoxyaryl | 1 |
| 24 | 40-and-over | 1 |
| 25 | 47/68 | 1 |
| 26 | 4d-transition-metal-doped | 1 |
| 27 | 5,6-epoxide | 1 |
| 28 | 5-htt-linked | 1 |
| 29 | 500-lux | 1 |
| 30 | abciximab/ticlopidin/aspirin-treated | 1 |
| 31 | acrh-treated | 1 |
| 32 | acrydite | 1 |
| 33 | adjustment-disorder | 1 |
| 34 | aerials | 1 |
| 35 | alcohol/chlorhexidine | 1 |
| 36 | alcoholic-septic | 1 |
| 37 | almond-consuming | 1 |
| 38 | alpha-blocker-naive | 2 |
| 39 | amino/amine | 1 |
| 40 | antónio | 1 |
| 41 | ap-exposed | 1 |
| 42 | apigenin-treated | 3 |
| 43 | apigenintreated | 1 |
| 44 | ar-6-treated | 1 |
| 45 | ar/asr | 1 |
| 46 | ara-administrated | 1 |
| 47 | arsonate | 1 |
| 48 | atv-treatment | 1 |
| 49 | authors.two | 1 |
| 50 | azl-m/cld | 2 |
| 51 | boc-containing | 2 |
| 52 | bol-treated | 2 |
| 53 | borates-bo3 | 1 |
| 54 | bpa-treated | 2 |
| 55 | butein-treated | 1 |
| 56 | ca-fed | 2 |
| 57 | carbometh-oxy | 1 |
| 58 | ccpi-containing | 1 |
| 59 | cediranib-containing | 1 |
| 60 | cf-treated | 3 |
| 61 | cgx-treated | 1 |
| 62 | cholecalciferol-supplemented | 2 |
| 63 | cokriging | 1 |
| 64 | compression-treated | 1 |
| 65 | conivaptan-treated | 1 |
| 66 | consumer-run | 1 |
| 67 | control/auriculotherapy | 1 |
| 68 | control/experimental | 1 |
| 69 | conventional-method | 1 |
| 70 | coumestan-treated | 1 |
| 71 | cr-fed | 1 |
| 72 | cultural/linguistic | 1 |
| 73 | da-9601-treated | 2 |
| 74 | daphnetin-treated | 1 |
| 75 | data.three | 1 |
| 76 | dbaa-treated | 1 |
| 77 | dbp-only | 2 |
| 78 | dexamethasone-containing | 1 |
| 79 | dibenzylamido | 1 |
| 80 | dinitroamino | 1 |
| 81 | discovery/validation | 1 |
| 82 | dm/chd | 1 |
| 83 | drug-switching | 1 |
| 84 | effects.clinical | 1 |
| 85 | eifferent | 1 |
| 86 | electropolymerizable | 2 |
| 87 | emg- | 1 |
| 88 | enalapril-hydrochlorothiazide | 2 |
| 89 | enoximone-treated | 1 |
| 90 | eplerenone-treated | 9 |
| 91 | ester-coo | 1 |
| 92 | eth-oxy | 1 |
| 93 | ethno-racial | 3 |
| 94 | evacetrapib-treated | 1 |
| 95 | evar-related | 1 |
| 96 | evogliptin-treated | 1 |
| 97 | exposure-level | 1 |
| 98 | f145 | 2 |
| 99 | fbg-treated | 1 |
| 100 | fgf-treated | 4 |
| 101 | fibrillogenic | 1 |
| 102 | filamenting | 1 |
| 103 | five-viscera | 3 |
| 104 | four-doses | 1 |
| 105 | furanodiene-treated | 1 |
| 106 | ground/heat-treated | 1 |
| 107 | ground/non-heat-treated | 1 |
| 108 | guadino | 1 |
| 109 | hcd-alone | 1 |
| 110 | high-fluorine | 3 |
| 111 | hr-treated | 1 |
| 112 | ht/db | 1 |
| 113 | iacr-iach | 1 |
| 114 | ifx/ssz+hcq | 1 |
| 115 | implants.three | 1 |
| 116 | imrt+3dcrt | 2 |
| 117 | intervention.one | 1 |
| 118 | intervention/support | 1 |
| 119 | interviews/focus | 2 |
| 120 | involved.three | 1 |
| 121 | ir+sjhxt | 1 |
| 122 | isopentene | 1 |
| 123 | isspp-treated | 1 |
| 124 | jinsane-treated | 5 |
| 125 | least-researched | 1 |
| 126 | lgi/hgi | 1 |
| 127 | lido-lido | 4 |
| 128 | lovastatin-placebo | 3 |
| 129 | low-fat-fed | 1 |
| 130 | low-solidarity | 1 |
| 131 | low/high-fat | 1 |
| 132 | low/low-intermediate | 3 |
| 133 | lp/hp | 1 |
| 134 | m-turp/b-turp | 2 |
| 135 | medium-/low-potency | 2 |
| 136 | metal-exposed | 2 |
| 137 | metaphosphate | 1 |
| 138 | methoxynaphthalene | 1 |
| 139 | methyl-carboxyl-ate | 1 |
| 140 | microcapsule-treated | 2 |
| 141 | militant | 1 |
| 142 | morse-tapered | 1 |
| 143 | msdc-0160-treated | 1 |
| 144 | nanocapsules-treated | 2 |
| 145 | new-model | 1 |
| 146 | newly-defined | 1 |
| 147 | nfv-treatment | 1 |
| 148 | no-ae | 2 |
| 149 | no-compression | 3 |
| 150 | no-reminder | 1 |
| 151 | non-bns | 1 |
| 152 | non-cephalosporin-based | 1 |
| 153 | non-chemotherapy | 8 |
| 154 | non-classified | 2 |
| 155 | non-gcae | 1 |
| 156 | non-impulsive | 1 |
| 157 | non-ohqi | 1 |
| 158 | non-pdt | 1 |
| 159 | non-pheromonal | 4 |
| 160 | non-prototypical | 1 |
| 161 | non-pvd | 1 |
| 162 | non-td | 3 |
| 163 | nonadjuvanted-vaccine | 1 |
| 164 | nonstigmatized | 1 |
| 165 | nzl-treated | 2 |
| 166 | odd-numbered | 15 |
| 167 | oil-infused | 3 |
| 168 | oligonucleosome-sized | 1 |
| 169 | olm-treated | 1 |
| 170 | omom | 2 |
| 171 | ortho-dihydroxy | 1 |
| 172 | oswe-treated | 2 |
| 173 | ovx+mlt | 1 |
| 174 | pee-epee | 1 |
| 175 | peg-treated | 3 |
| 176 | pemetrexed-containing | 5 |
| 177 | phosphazene | 2 |
| 178 | phthalimido | 1 |
| 179 | phy-sicians/lab | 1 |
| 180 | picky/non-picky | 1 |
| 181 | picolinamide | 1 |
| 182 | picolinyl | 1 |
| 183 | placebo-prednisolone | 2 |
| 184 | ple-treated | 1 |
| 185 | pnp-treated | 1 |
| 186 | postmicturition-only | 1 |
| 187 | ppci-alone | 1 |
| 188 | pre-optimised | 4 |
| 189 | precut-cannulation | 1 |
| 190 | propranolol/hydrochlorothiazide-treated | 2 |
| 191 | reinstitutionalization | 1 |
| 192 | rhfgf-2-treated | 1 |
| 193 | right-to-life | 2 |
| 194 | risk/intervention | 1 |
| 195 | s-ketamine-pca | 1 |
| 196 | sea-caged | 1 |
| 197 | seeds/control | 1 |
| 198 | selegiline/rasagiline | 1 |
| 199 | selenium-treatment | 1 |
| 200 | self-vaginal | 1 |
| 201 | single-medication | 1 |
| 202 | small-n | 2 |
| 203 | so3h | 1 |
| 204 | socs3-based | 1 |
| 205 | sofosbuvir/pegifn/rbv | 1 |
| 206 | spirotetrahydroselenophene | 1 |
| 207 | standard-method | 1 |
| 208 | standard-model | 1 |
| 209 | std-risk | 1 |
| 210 | steroid-administered | 1 |
| 211 | stimulant-containing | 1 |
| 212 | sulfonamide-treated | 1 |
| 213 | superfamilial | 1 |
| 214 | supplement-administration | 1 |
| 215 | tbc-treated | 1 |
| 216 | tc-dcr | 6 |
| 217 | tcbz-treated | 1 |
| 218 | techniques.three | 1 |
| 219 | tensorial | 2 |
| 220 | thre | 1 |
| 221 | ti-oh | 1 |
| 222 | to-treated | 1 |
| 223 | tow | 11 |
| 224 | trans-dehydrocrotonin-treated | 1 |
| 225 | treatment/normative | 1 |
| 226 | treatments.six | 1 |
| 227 | two | 128,466 |
| 228 | two-drug-combination | 1 |
| 229 | uniform-sized | 1 |
| 230 | unsponsored | 1 |
| 231 | us+ns | 2 |
| 232 | vcd- | 1 |
| 233 | vector+gdcl3 | 1 |
| 234 | vit-c-supplemented | 1 |
| 235 | wheat-cereal | 1 |
| 236 | wire-guided-cannulation | 1 |
| 237 | wlc-only | 1 |
| 238 | wyfc-lnd | 1 |
| 239 | younger/older/elderly | 1 |
| 240 | –nh– | 1 |
| 1 | vcd- | 1 |
| 2 | emg- | 1 |
| 3 | 2d-3 | 2 |
| 4 | 4,343 | 1 |
| 5 | vector+gdcl3 | 1 |
| 6 | borates-bo3 | 1 |
| 7 | 2,904 | 1 |
| 8 | f145 | 2 |
| 9 | 27,955 | 1 |
| 10 | 47/68 | 1 |
| 11 | 3,178 | 2 |
| 12 | 22,479 | 1 |
| 13 | s-ketamine-pca | 1 |
| 14 | five-viscera | 3 |
| 15 | phy-sicians/lab | 1 |
| 16 | ht/db | 1 |
| 17 | fibrillogenic | 1 |
| 18 | alcoholic-septic | 1 |
| 19 | cultural/linguistic | 1 |
| 20 | ca-fed | 2 |
| 21 | cr-fed | 1 |
| 22 | low-fat-fed | 1 |
| 23 | sea-caged | 1 |
| 24 | least-researched | 1 |
| 25 | non-classified | 2 |
| 26 | 5-htt-linked | 1 |
| 27 | newly-defined | 1 |
| 28 | 4d-transition-metal-doped | 1 |
| 29 | odd-numbered | 15 |
| 30 | morse-tapered | 1 |
| 31 | steroid-administered | 1 |
| 32 | unsponsored | 1 |
| 33 | socs3-based | 1 |
| 34 | non-cephalosporin-based | 1 |
| 35 | pre-optimised | 4 |
| 36 | metal-exposed | 2 |
| 37 | ap-exposed | 1 |
| 38 | oil-infused | 3 |
| 39 | msdc-0160-treated | 1 |
| 40 | da-9601-treated | 2 |
| 41 | rhfgf-2-treated | 1 |
| 42 | ar-6-treated | 1 |
| 43 | dbaa-treated | 1 |
| 44 | bpa-treated | 2 |
| 45 | evacetrapib-treated | 1 |
| 46 | tbc-treated | 1 |
| 47 | sulfonamide-treated | 1 |
| 48 | propranolol/hydrochlorothiazide-treated | 2 |
| 49 | ple-treated | 1 |
| 50 | microcapsule-treated | 2 |
| 51 | jinsane-treated | 5 |
| 52 | furanodiene-treated | 1 |
| 53 | enoximone-treated | 1 |
| 54 | eplerenone-treated | 9 |
| 55 | oswe-treated | 2 |
| 56 | cf-treated | 3 |
| 57 | fgf-treated | 4 |
| 58 | fbg-treated | 1 |
| 59 | peg-treated | 3 |
| 60 | acrh-treated | 1 |
| 61 | bol-treated | 2 |
| 62 | nzl-treated | 2 |
| 63 | olm-treated | 1 |
| 64 | conivaptan-treated | 1 |
| 65 | coumestan-treated | 1 |
| 66 | butein-treated | 1 |
| 67 | apigenin-treated | 3 |
| 68 | trans-dehydrocrotonin-treated | 1 |
| 69 | abciximab/ticlopidin/aspirin-treated | 1 |
| 70 | daphnetin-treated | 1 |
| 71 | evogliptin-treated | 1 |
| 72 | compression-treated | 1 |
| 73 | to-treated | 1 |
| 74 | pnp-treated | 1 |
| 75 | isspp-treated | 1 |
| 76 | hr-treated | 1 |
| 77 | nanocapsules-treated | 2 |
| 78 | ground/non-heat-treated | 1 |
| 79 | ground/heat-treated | 1 |
| 80 | cgx-treated | 1 |
| 81 | tcbz-treated | 1 |
| 82 | apigenintreated | 1 |
| 83 | evar-related | 1 |
| 84 | ara-administrated | 1 |
| 85 | vit-c-supplemented | 1 |
| 86 | cholecalciferol-supplemented | 2 |
| 87 | oligonucleosome-sized | 1 |
| 88 | uniform-sized | 1 |
| 89 | nonstigmatized | 1 |
| 90 | dm/chd | 1 |
| 91 | azl-m/cld | 2 |
| 92 | wyfc-lnd | 1 |
| 93 | standard-method | 1 |
| 94 | conventional-method | 1 |
| 95 | non-td | 3 |
| 96 | non-pvd | 1 |
| 97 | no-ae | 2 |
| 98 | non-gcae | 1 |
| 99 | picolinamide | 1 |
| 100 | 5,6-epoxide | 1 |
| 101 | enalapril-hydrochlorothiazide | 2 |
| 102 | pee-epee | 1 |
| 103 | data.three | 1 |
| 104 | involved.three | 1 |
| 105 | techniques.three | 1 |
| 106 | implants.three | 1 |
| 107 | right-to-life | 2 |
| 108 | electropolymerizable | 2 |
| 109 | spirotetrahydroselenophene | 1 |
| 110 | methoxynaphthalene | 1 |
| 111 | isopentene | 1 |
| 112 | phosphazene | 2 |
| 113 | nonadjuvanted-vaccine | 1 |
| 114 | alcohol/chlorhexidine | 1 |
| 115 | selegiline/rasagiline | 1 |
| 116 | amino/amine | 1 |
| 117 | high-fluorine | 3 |
| 118 | intervention.one | 1 |
| 119 | hcd-alone | 1 |
| 120 | ppci-alone | 1 |
| 121 | placebo-prednisolone | 2 |
| 122 | thre | 1 |
| 123 | methyl-carboxyl-ate | 1 |
| 124 | metaphosphate | 1 |
| 125 | low/low-intermediate | 3 |
| 126 | arsonate | 1 |
| 127 | 2',3'-bisphosphorothioate | 1 |
| 128 | acrydite | 1 |
| 129 | alpha-blocker-naive | 2 |
| 130 | non-impulsive | 1 |
| 131 | treatment/normative | 1 |
| 132 | cokriging | 1 |
| 133 | drug-switching | 1 |
| 134 | 'rolling | 1 |
| 135 | almond-consuming | 1 |
| 136 | cediranib-containing | 1 |
| 137 | boc-containing | 2 |
| 138 | pemetrexed-containing | 5 |
| 139 | dexamethasone-containing | 1 |
| 140 | ccpi-containing | 1 |
| 141 | stimulant-containing | 1 |
| 142 | filamenting | 1 |
| 143 | 320-μg | 2 |
| 144 | so3h | 1 |
| 145 | iacr-iach | 1 |
| 146 | ti-oh | 1 |
| 147 | lgi/hgi | 1 |
| 148 | non-ohqi | 1 |
| 149 | std-risk | 1 |
| 150 | effects.clinical | 1 |
| 151 | non-prototypical | 1 |
| 152 | wheat-cereal | 1 |
| 153 | ethno-racial | 3 |
| 154 | superfamilial | 1 |
| 155 | tensorial | 2 |
| 156 | self-vaginal | 1 |
| 157 | non-pheromonal | 4 |
| 158 | control/experimental | 1 |
| 159 | standard-model | 1 |
| 160 | new-model | 1 |
| 161 | exposure-level | 1 |
| 162 | seeds/control | 1 |
| 163 | 2',3'-o-acyl | 1 |
| 164 | 3,4-dimethyl | 2 |
| 165 | 2,2'-alkyl | 1 |
| 166 | 2',3'-o-silyl | 1 |
| 167 | 4-eth-oxy-phenyl | 1 |
| 168 | picolinyl | 1 |
| 169 | 4-phenoxyaryl | 1 |
| 170 | 2,3-hydroxyl | 1 |
| 171 | 2,3-dihydroxyl | 1 |
| 172 | 3,5-dihydroxyl | 1 |
| 173 | omom | 2 |
| 174 | small-n | 2 |
| 175 | no-compression | 3 |
| 176 | single-medication | 1 |
| 177 | discovery/validation | 1 |
| 178 | wire-guided-cannulation | 1 |
| 179 | precut-cannulation | 1 |
| 180 | two-drug-combination | 1 |
| 181 | supplement-administration | 1 |
| 182 | reinstitutionalization | 1 |
| 183 | risk/intervention | 1 |
| 184 | consumer-run | 1 |
| 185 | lovastatin-placebo | 3 |
| 186 | lido-lido | 4 |
| 187 | dibenzylamido | 1 |
| 188 | phthalimido | 1 |
| 189 | antónio | 1 |
| 190 | guadino | 1 |
| 191 | dinitroamino | 1 |
| 192 | ester-coo | 1 |
| 193 | two | 128,466 |
| 194 | 'two | 3 |
| 195 | authors.two | 1 |
| 196 | lp/hp | 1 |
| 197 | m-turp/b-turp | 2 |
| 198 | ifx/ssz+hcq | 1 |
| 199 | tc-dcr | 6 |
| 200 | no-reminder | 1 |
| 201 | adjustment-disorder | 1 |
| 202 | 40-and-over | 1 |
| 203 | ar/asr | 1 |
| 204 | four-doses | 1 |
| 205 | aerials | 1 |
| 206 | us+ns | 2 |
| 207 | non-bns | 1 |
| 208 | interviews/focus | 2 |
| 209 | low/high-fat | 1 |
| 210 | non-pdt | 1 |
| 211 | ovx+mlt | 1 |
| 212 | militant | 1 |
| 213 | selenium-treatment | 1 |
| 214 | nfv-treatment | 1 |
| 215 | atv-treatment | 1 |
| 216 | eifferent | 1 |
| 217 | imrt+3dcrt | 2 |
| 218 | intervention/support | 1 |
| 219 | ir+sjhxt | 1 |
| 220 | 2000-u | 1 |
| 221 | sofosbuvir/pegifn/rbv | 1 |
| 222 | tow | 11 |
| 223 | treatments.six | 1 |
| 224 | 500-lux | 1 |
| 225 | 1,000-mg/day | 2 |
| 226 | 3,000-mg/day | 2 |
| 227 | medium-/low-potency | 2 |
| 228 | 1.0-gy | 4 |
| 229 | picky/non-picky | 1 |
| 230 | wlc-only | 1 |
| 231 | postmicturition-only | 1 |
| 232 | dbp-only | 2 |
| 233 | younger/older/elderly | 1 |
| 234 | control/auriculotherapy | 1 |
| 235 | non-chemotherapy | 8 |
| 236 | low-solidarity | 1 |
| 237 | eth-oxy | 1 |
| 238 | carbometh-oxy | 1 |
| 239 | ortho-dihydroxy | 1 |
| 240 | –nh– | 1 |